Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPROACH: Apalutamide + ADT +/- Local Treatment in mHSPC
NCT05649943Phase 3Recruiting
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2023
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of apalutamide in prostate cancer (PCa), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Mar 2023; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05649943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649943.